Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03848221 · ClinicalTrials.gov registry record · Phase 4
Direct Application of Systane Complete to Contact Lenses
A Phase 4 study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 4
- Development phase
- 73
- Enrollment target
NCT03848221 is a Phase 4 study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 73 participants.
The verdict
NCT03848221, a Phase 4 study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 73 participants
- Enrollment target
Study Summary
A common first line treatment for patients with dryness symptoms or contact lens discomfort is the application of artificial tears or rewetting drops, respectively. Rewetting drops are specifically formulated for use with contact lenses while artificial tears are indicated for dry eye. Modern rewetting drops and artificial tears have similar formulations with similar preservatives, preservatives that have been shown to be compatible with contact lenses. While rewetting drops and artificial tears are regulated under different U.S. Food \& Drug Administration policies, artificial tears are not specifically indicated for direct use with contact lenses. Nevertheless, clinicians commonly prescribe artificial tears to contact lens wearers likely because newer formulations of artificial tear have the potential to outperform available rewetting drops. The safety and efficacy of using artificial tears with contact lenses for the treatment of discomfort is supported by Caffery and Josephson and Ozkan and Papas who found that artificial tears significantly reduces dryness symptoms in contact lens wearers. Thus, the purpose of this study is to test the safety of directly applying a new artificial tear, Systane Complete, to the contact lens wearing eye and its ability to alleviate symptoms while wearing contact lenses during the day.
Interventions
- DRUG Systane Complete
- DRUG Sensitive Eyes Rewetting Drops
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2019-05-28 |
| Est. Completion | 2019-10-20 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03848221
The ClinicalTrials.gov registry entry for NCT03848221 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 73 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Systane Complete is the first listed.
NCT03848221 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03848221 about?
NCT03848221 is a clinical study titled "Direct Application of Systane Complete to Contact Lenses". A common first line treatment for patients with dryness symptoms or contact lens discomfort is the application of artificial tears or rewetting drops, respectively. Rewetting drops are specifically formulated for use with contact lenses while artificial tears are indicated for dry eye. Modern rewett...
What is the current status of trial NCT03848221?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 73 participants. The study started on 2019-05-28. Estimated completion is 2019-10-20.
What interventions are being tested in trial NCT03848221?
The interventions under investigation include: Systane Complete (DRUG), Sensitive Eyes Rewetting Drops (DRUG).
Who is sponsoring clinical trial NCT03848221?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.